Sanofi-aventis and UCSF to Collaborate on Development of Diabetes Therapies

Shares

The University of California, San Francisco (UCSF) and sanofi-aventis have formed two new research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation. The second collaboration is an oncology partnership that will focus on project-based collaboration to accelerate the progression of research through the clinical proof of concept stage.
Sanofi-aventis will be the first industry partner for UCSF’s Program for Breakthrough Biomedical Research (PBBR). The PBBR program awards funding to projects of potentially high impact, greater creativity and with an innovative approach to scientific discovery. The partnership with UCSF enhances sanofi-aventis’ approach of setting up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.
Under the terms of the agreement, a UCSF/sanofi-aventis Joint Steering Committee will choose from among UCSF-generated proposals identified for their scientific excellence. Sanofi-aventis will fund up to five grants a year, with additional funds being available for students or fellows to intern at sanofi-aventis to conduct collaborative research.  To further this exchange of ideas, sanofi-aventis will fund an annual research forum that will bring together sanofi-aventis and UCSF researchers to share knowledge and perspectives on relevant scientific matters and to review progress of research projects funded through the collaboration.

Leave a Reply

avatar
3000
  Subscribe  
Notify of
Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.